A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

NCT03443453 | Completed Phase 1 FDA Drug

• 1 other identifier: MIV-711-102
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-Center, Randomised, 4-Period, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Effect of Food on Pharmacokinetics following Single Doses of MIV-711 Capsule and Tablet Formulations in Healthy Volunteers

Conditions

Healthy

Outcome Measures

Primary Outcomes (6)

• Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t)

  The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations.

  0 to 72 hours post dose

• Area under the concentration-time curve, from time 0 extrapolated to infinity (AUC0-inf)

  The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations.

  0 to 72 hours post dose

• Maximum observed concentration (Cmax)

  The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations.

  0 to 72 hours post dose

• Time to reach maximum observed concentration (Tmax)

  The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations.

  0 to 72 hours post dose

• Apparent terminal elimination rate constant (Kel)

  The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations.

  0 to 72 hours post dose

• Apparent terminal elimination half-life (T½)

  The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations.

  0 to 72 hours post dose

Secondary Outcomes (4)

• The number and severity of AEs/SAE

  from study start until 7+/-2 days after the last study drug administration

• The number of clinically significant abnormal lab results

  from study start until 7+/-2 days after the last study drug administration

• The number of clinically significant ECG abnormalities

  from study start until 7+/-2 days after the last study drug administration

• The number of clinically significant physical examination abnormalities

  from study start until 7+/-2 days after the last study drug administration

Study Arms (2)

MIV-711 ABCD

EXPERIMENTAL

Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).

Drug: MIV-711

MIV-711 CDAB

EXPERIMENTAL

Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).

Drug: MIV-711

Interventions

MIV-711 DRUG

MIV-711 administered as tablets and capsules at four occasions

MIV-711 ABCD; MIV-711 CDAB

Eligibility Criteria

• Age: 19 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, adult, male or female, 19-55 years of age, inclusive, at screening.
• Body mass index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2 at screening.
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.
• If not a menopausal female or surgically sterile male or female, subjects must be willing to practice at least one of the in the CSP described highly effective methods of birth control for at least a (partner's) menstrual cycle before and for 3 months after study drug administration.
• For a female of non-childbearing potential: must have undergone one of the following sterilization procedures at least 6 months prior to the first dose:
• hysteroscopic sterilization;
• bilateral tubal ligation or bilateral salpingectomy;
• hysterectomy;
• bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 2 years prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status as per PI or designee judgment.

You may not qualify if:

• History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
• History of any illness that, in the opinion of the PI or designee, that could affect the action, absorption, or disposition of MIV-711 or may confound the results of the study or poses an additional risk to the subject by their participation in the study.
• History or presence of known structural cardiac abnormalities, syncope, cardiac conduction problems (first, second, or third degree heart blocks, bundle branch block, or incomplete block, atrial fibrillation and/or paroxysmal atrial fibrillation, sick sinus syndrome or prolonged QTc interval), inappropriate sinus bradycardia, deviant ECG morphology or exercise related cardiac events.
• Unable to refrain from or anticipates the use of:
• Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dose and throughout the study. Medication listed as part of acceptable birth control methods will be allowed.
• Any drugs known to be inducers of CYP enzymes for 28 days prior to the first dose of study drug and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/PD interaction with study drug.
• Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study.
• Hormone replacement therapy will also be allowed.
• Subjects on a stable dose (at least 3 months) of thyroid medication will be allowed.
• An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study.

Sponsors & Collaborators

• Medivir: lead

Study Sites (1)

Celerion

Lincoln, Nebraska, 68502, United States

Location

MeSH Terms

Interventions

MIV-711

Study Officials

• Allen Hunt

  Celerion

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 22, 2018
• First Posted: February 23, 2018
• Study Start: January 19, 2018
• Primary Completion: February 17, 2018
• Study Completion: February 17, 2018
• Last Updated: February 23, 2018

Record last verified: 2018-02

Locations

US (1)